Latest Irish Investment Fund (IRL) Headlines 77.6%

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Irish Investment Fund (IRL) Headlines

77.6% Return Seen to Date on SmarTrend New Ireland Fund Call (IRL)
Comtex SmarTrend(R) - Thu Mar 13, 4:41PM CDT
SmarTrend identified an Uptrend for New Ireland Fund (NYSE:IRL) on September 6th, 2012 at $7.95. In approximately 18 months, New Ireland Fund has returned 77.60% as of today's recent price of $14.11.

New Ireland Fund Up 83.1% Since SmarTrend Uptrend Call (IRL)
Comtex SmarTrend(R) - Thu Mar 06, 10:59AM CST
SmarTrend identified an Uptrend for New Ireland Fund (NYSE:IRL) on September 6th, 2012 at $7.95. In approximately 18 months, New Ireland Fund has returned 83.13% as of today's recent price of $14.55.

The New Ireland Fund, Inc. Monthly Portfolio Update
Marketwire - Mon Mar 03, 1:56PM CST
The New Ireland Fund, Inc. (NYSE: IRL) today released an updated Monthly portfolio statement as of February 28, 2014.

The New Ireland Fund - Quarterly Portfolio Update as of January 31, 2014
Marketwire - Thu Feb 27, 1:17PM CST
Investment Objective: The New Ireland Fund, Inc., (NYSE: IRL) a closed-end diversified investment company, seeks long-term capital appreciation through investment of at least 80% of its assets in a portfolio of Irish securities. The Fund is designed for U.S. and other investors who wish to participate in the Irish securities markets.

New Ireland Fund Shares Up 79.1% Since SmarTrend's Buy Recommendation (IRL)
Comtex SmarTrend(R) - Thu Feb 27, 9:34AM CST
SmarTrend identified an Uptrend for New Ireland Fund (NYSE:IRL) on September 6th, 2012 at $7.95. In approximately 18 months, New Ireland Fund has returned 79.11% as of today's recent price of $14.23.

Uptrend Call Working As New Ireland Fund Stock Rises 60.9% (IRL)
Comtex SmarTrend(R) - Wed Feb 05, 11:01AM CST
SmarTrend identified an Uptrend for New Ireland Fund (NYSE:IRL) on September 6th, 2012 at $7.95. In approximately 17 months, New Ireland Fund has returned 60.86% as of today's recent price of $12.78.

65.4% Return Seen to Date on SmarTrend New Ireland Fund Call (IRL)
Comtex SmarTrend(R) - Wed Jan 29, 9:43AM CST
SmarTrend identified an Uptrend for New Ireland Fund (NYSE:IRL) on September 6th, 2012 at $7.95. In approximately 17 months, New Ireland Fund has returned 65.39% as of today's recent price of $13.14.

New Ireland Fund Up 68.0% Since SmarTrend Uptrend Call (IRL)
Comtex SmarTrend(R) - Wed Jan 22, 9:12AM CST
SmarTrend identified an Uptrend for New Ireland Fund (NYSE:IRL) on September 6th, 2012 at $7.95. In approximately 17 months, New Ireland Fund has returned 68.03% as of today's recent price of $13.35.

The New Ireland Fund, Inc. Files Annual Report
Marketwire - Thu Jan 02, 9:47AM CST
The Board of Directors of The New Ireland Fund, Inc. (NYSE: IRL) is pleased to announce that it has filed its Annual Report for the year ended October 31, 2013 with the SEC on Form N-CSR. A full copy of the Annual Report is available on the Fund's Website at: www.newirelandfund.com. Shareholders may also receive a hard copy of the Fund's complete audited financial statements free of charge upon request. This may be done by writing to the Fund at:

The New Ireland Fund, Inc. Declares Annual Distribution
Marketwire - Tue Dec 10, 1:16PM CST
The Board of Directors of The New Ireland Fund, Inc. (NYSE: IRL) (the "Fund") has declared an annual distribution in the amount of $0.07 per share, which is wholly attributable to income. The distribution will be paid by way of cash dividend on December 30, 2013 to stockholders of record on December 20, 2013.

Irish Investment Fund (IRL) Stock Research Links

IRL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Findings on gMG Treatments by UCB at AANEM 2024

Updated Category News Views 127

UCB Highlights Innovations in Generalized Myasthenia Gravis Treatments at AANEM 2024 UCB, a prominent global biopharmaceutical company, is gearing up to present its latest findings in the management of generalized myasthenia gravis (gMG) at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. The event, which will also feature...

Continue Reading
Lysander Funds Shares New Distributions Estimates for ETFs

Updated Category News Views 131

Lysander Funds Shares New Distributions Estimates Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of...

Continue Reading
Empowering Girls: Pace Center's Initiatives for Growth

Updated Category News Views 350

Introduction to the Capital Campaign Pace Center for Girls Hillsborough is excited to announce its capital campaign aimed at expanding its capacity and enhancing the support provided to girls in the community. Through dedicated efforts such as education, counseling, and training, this campaign signifies a crucial step towards bettering the future for girls in Hillsborough...

Continue Reading
Bank of America Sees Growth in Loans, Deposits Amid Profit Rise

Updated Category News Views 284

Bank of America Reports Increased Earnings and Efficiency Bank of America Corp (NASDAQ: BAC) has announced strong financial results for the second quarter, showcasing impressive growth in loans, deposits, and overall profitability. The bank reported a net income of $7.1 billion, a slight increase from $6.9 billion the previous year, along with an earnings per share (EPS)...

Continue Reading
Investigating Manitex International: A Closer Look at MNTX

Updated Category News Views 72

Examining Fair Treatment for Manitex International Shareholders Ademi LLP has launched an investigation into Manitex International, Inc. (NASDAQ: MNTX) due to concerns about possible breaches of fiduciary duty related to its recent transaction with Tadano. This investigation raises important questions about whether shareholders are being treated fairly in the financial...

Continue Reading